Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3Phase 3 2Phase 1/2 1

Status

Terminated 4

Sponsor Class

INDUSTRY 4OTHER 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 2

Conditions

Neoplasms 3Prostatic Neoplasms 2

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × satraplatin × Clear all
NCT00313456 2012-05-10

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

Agennix

Phase 1 Terminated
25 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00125411 2012-03-26

Study of Satraplatin (JM-216) in Combination With Docetaxel

Agennix

Phase 1 Terminated
28 enrolled
Tumor-Agnostic

Neoplasms

NCT00329329 2012-03-23

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

Agennix

Phase 1 Terminated
24 enrolled
Tumor-Agnostic

Neoplasms

NCT00480623 2012-03-23

A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence

Agennix

Phase 1 Terminated
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡